Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 6/20 | 0.32 |
| ▸ | CA9 | Q16790 | 6/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9922336 | 0.91 | P2RY12 (0.48) | P2RY12PPARGGRM1MAPT | |
| SCHEMBL12177212 | 0.87 | P2RY12 (0.34) | P2RY12NAMPTMAPTBRD4CREBBP | |
| SCHEMBL12177245 | 0.87 | P2RY12 (0.38) | P2RY12TP53MAPTBRD4CREBBP | |
| SCHEMBL14228346 | 0.87 | P2RY12 (0.39) | P2RY12EPHX2 | |
| SCHEMBL13638502 | 0.86 | RAB9A (0.42) | P2RY12PPARGNAMPTMAPTBRD4 | |
| SCHEMBL9922887 | 0.84 | P2RY12 (0.49) | P2RY12PPARGMAPT | |
| SCHEMBL12177640 | 0.84 | ESR1 (0.39) | P2RY12PPARGNAMPTMAPT | |
| SCHEMBL14228568 | 0.83 | P2RY12 (0.39) | P2RY12PPARGNAMPTBRD4CREBBP | |
| SCHEMBL14113531 | 0.83 | P2RY12 (0.39) | P2RY12PPARGNAMPTTP53BRD4 | |
| SCHEMBL4687896 | 0.82 | P2RY12 (0.45) | P2RY12PPARGNAMPTTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | P2RY12 18/4885PPARG 301/4885GRM1 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.